Pharmacy Division

Taiwan

Pharmacy Division

Taiwan
SEARCH FILTERS
Time filter
Source Type

News Article | May 11, 2017
Site: globenewswire.com

At 31 March 2017, PHARMAGEST Group had consolidated revenue of €35.42 million, up significantly by 16.30% from the 2016 first quarter (€30.46 million). On a pro forma basis (like-for-like, excluding revenues from acquisitions: Dicsit Informatique, Noviatek, Sailendra, Caremeds-Multimeds), consolidated revenue amounted to €34.22 million, up 12.35% from the 2016 first quarter. : a top priority in 2017 will be the deployment of the new version of the LGPI application. Today known as a truly comprehensive software solutions for pharmacists, integrating extensions to patient medication management services, this new generation portal provides pharmacists access to new patient medication services management (and in particular, the medication adherence monitoring application, secure electronic messaging for the healthcare sector, etc.). Against the backdrop of population ageing and the wish of more than 80% of seniors to remain in their home, the complementary nature of the business activities of Malta Informatique (software solutions for elderly residential care facilities) and DICSIT Informatique (a comprehensive management solution for home-based care) combined with synergies from the operational and commercial teams, the outlook for continuing growth is positive for the Solutions for Health and Medical-Social Institutions Division . Conscious of the stakes associated with the transformation of the healthcare system, and particularly the challenges of connected health, Pharmagest Group through its Solutions for e-Health Division, is enhancing its global compliance offering: by acquiring a strategic stake in UK companies, Caremeds-Multimeds, in 2017 the Solutions for e-Health Division will complete its product range around Dose Administration Aids services or DAAs (Préparation des Doses à Administrer or PDA) and intends to expand its market share in this sector in Europe. After one full year of operations (2016), the Leasa by Nanceo platform has demonstrated its benefits: reliability and performance but also confidentiality and security. For 2017, must significantly increase the file acceptance rate (in particular for customers other than pharmacies) and in parallel, promote the deployment of its mobile application. Pharmagest Group is the French pharmacy information technology leader, with a 43.5% market share and more than 900 employees. The Group's strategy is based on a core business, information technology innovation to improve health care, and on the development of two priorities: 1/ Services and technologies for healthcare professionals, with a focus on assisting pharmacies in the area of patient medication compliance; and 2/ technologies for improving the efficacy of healthcare systems. To roll out that strategy, Pharmagest Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for pharmaceutical laboratories, connected health devices and apps, and a sales financing marketplace. These businesses are now divided into four divisions: The Solutions for Pharmacy Division - Europe, the Solutions for Health and Medical-Social Institutions Division, the Solutions for e-Health Division, and the Fintech Division. Listed on Euronext Paris(TM) - Compartment B Indices: CAC® SMALL and CAC® All-Tradable par inclusion Eligible for the Long-Only Deferred Settlement Service (SRD) ISIN: FR 0012882389 - Reuters: PHA.PA  - Bloomberg: - PMGI FP For all the latest news go to www.pharmagest.com Analyst and Investor Relations: Chief Administrative and Financial Officer: Jean-Yves SAMSON Tel. +33 (0)3 83 15 90 67 - jean-yves.samson@pharmagest.com


Wu N.-C.,Pharmacy Division | Su S.-M.,Pharmacy Division | Su S.-M.,Kaohsiung Medical University | Lin T.-J.,Tajen University | And 5 more authors.
Anti-Cancer Drugs | Year: 2015

This study aimed to investigate the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and the prognosis of colorectal cancer (CRC) patients undergoing 5-fluorouracil (5-FU)-based chemotherapy in Taiwan. We investigated 126 CRC cases. The most common polymorphisms C677T (rs1801133) and A1298C (rs1801131) in MTHFR were genotyped using PCR-restriction fragment length polymorphism. The frequencies of C677T and A1298C were further compared with those in the HapMap database for Whites and Asians. In this study, we found that TT-homozygosity at MTHFR C677T was significantly associated with survival in CRC patients [P<0.001; 95% confidence interval (CI)=0.068-0.212]. In CRC patients receiving 5-FU-based chemotherapy, the TT genotype at C677T was also significantly associated with survival (P=0.001; 95% CI=0.113-0.400) and recurrence after surgery (P<0.001; 95% CI=0.295-0.609). The A1298C genotypes had a significant impact on survival (χ 2 =7.103; P=0.029). The MTHFR A1298C CC genotype may increase the risk of death in Taiwanese CRC patients. The MTHFR C677T TT genotype was present at a lower frequency in our CRC patients than in the HapMap Asian population, but the frequency was similar to that in Whites in the HapMap database. The distribution of MTHFR A1298C genotypes was similar in our CRC and in the HapMap Asian population, but was different from that in the White population. This study suggested that MTHFR C677T and A1298C are associated with prognosis in CRC patients undergoing 5-FU-based chemotherapy. © 2015 Wolters Kluwer Health, Inc. All rights reserved.


News Article | November 16, 2016
Site: globenewswire.com

The PHARMAGEST Group's turnover in Q3 2016 rose 17.20% year-on-year to €30 million. In the first nine months of 2016, the PHARMAGEST Group's turnover rose 14.36% to €93.53 million, compared with 30 September 2015. The PHARMAGEST Group is the French leader in pharmacy information technology, with a 43.5% share of the market and over 860 employees. The strategy of the PHARMAGEST Group is based on a core business - innovating in information technology to improve healthcare - and on the development of two priority focuses: services and technologies for healthcare professionals, notably support for pharmacists in monitoring patient compliance; and technology for improving the efficacy of healthcare systems. To roll out that strategy, the PHARMAGEST Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for laboratories, connected health devices and apps, and a sales financing marketplace. These businesses are divided into 4 Divisions: the Solutions for Pharmacy Division - Europe, the Solutions for Sanitary and Medico-Social Establishments Division, the Solutions for e-Health Division, and the FinTech Division. Listed on Euronext Paris(TM) - Compartment B Indices: ENTERNEXT TECH 40, CAC ® SMALL and CAC ® All-Tradable by inclusion Eligible for the Long-Only Deferred Settlement Service (SRD) ISIN: FR0012882389 - Reuters: PHA.PA - Bloomberg: PMGI FP For all the latest news, go to www.pharmagest.com Chairman of the Board of Directors Thierry CHAPUSOT


News Article | February 28, 2017
Site: globenewswire.com

MONITORING COMPLIANCE: TWO ACQUISITIONS THAT OPEN THE DOOR TO THE UK MARKET                           Treatment compliance: a public health issue and a strategic priority for the PHARMAGEST Group Through these two acquisitions, the PHARMAGEST Group continues to build its technology and services infrastructure around the patient, particularly in areas designed to extend the length of time people can be cared for in their homes, as well as e-health services, both areas in which pharmacists can legitimately claim to play a front-line coordination role. The PHARMAGEST Group's offering includes a range of solutions to help pharmacists effectively counter the main reasons for treatment regime non-compliance. The LSO compliance monitoring software is a module integrated into the pharmacy management software. Its functions include the ability to centralise, share and monitor all the pharmacies' patient health data. Taking a holistic approach, these solutions are built into the pharmacy management software, LGPI Global Services®, which simplifies use and increases their efficacy. Improving patient health and care practices and reducing costs have been an integral part of the PHARMAGEST Group's forward-looking development strategy for many years by offering innovative systems aimed at working with all the links in the care chain to educate and inform patients. External growth at a crucial time for the pharmaceutical market The patient has become the central focus of all European health systems. This new environment represents a wide-ranging change in the organisation of our health system. For example, French Health Authorities introduced payment on a fee-per-service basis for pharmacists in 2016, enacting one of the key aspects of the reform to their system of payment. Dose dispensing is not yet regulated in France, but it is often done in practice within the pharmacy. 2017 will be a pivotal year on this point: trials are currently under way to switch from box packaging to removable doses in a blister pack. Generic pharmaceutical companies are also working on products and dosages suitable for use in these new packaging systems. The care homes market, which is targeted by the CAREMEDS range, is expanding rapidly: 80% of the 7,752 care homes in France do not have secure and fully traceable medication management systems in place. This is also true with most European care homes. The potential of the emerging home healthcare market is 120 patients per pharmacy. Against this backdrop, the acquisition of CAREMEDS and MULTIMEDS positions the PHARMAGEST Group as the first pharmacy software developer to offer a stand-out suite of solutions with: Thierry CHAPUSOT, Chairman of the Board of Directors, PHARMAGEST Group, commented: "these two acquisitions fit seamlessly into the Group's e-health strategy and its positioning in the treatment compliance market. They not only enable us to offer a comprehensive range of medication compliance solutions for pharmacists and care homes, but also position us as the single point of call for them." Specifically, "the CAREMEDS range stands out as innovative in the PHARMAGEST Group's line-up. Already on the market in many European countries, the MULTIMEDS pill dispenser range opens many doors to us in European pharmacies. CAREMEDS' medication management and traceability software for care homes is particularly tailored to the Anglo-Saxon market and paves the way for the PHARMAGEST Group to penetrate the care home market - initially in the UK and soon after in other countries." He concluded: "Our aim is to step up this offering in the very near term in Europe. It will also be used as part of our international growth strategy." John ROWLEY, Chairman and founder of CAREMEDS and MULTIMEDS, said: "When CAREMEDS and MULTIMEDS started in 2012, the landscape could not have been more different to what it is today. Back then we were a start-up in pharmacy software and compliance packaging systems with a laser guided focus on improving outcomes for patients. Today our products are used in eight European countries, we service over 2,000 care homes in the UK through our pharmacy users and have two major new products due for release in the coming weeks." He added: "The strategic deal with the PHARMAGEST Group will scale the CAREMEDS software and MULTIMEDS packaging system to a new level by leveraging the PHARMAGEST Group's impressive customer base of over 10,000 pharmacies and more than 1,500 care homes which currently use PHARMAGEST solutions in France, Belgium and Luxembourg." The PHARMAGEST Group is there for patients at every stage of the care pathway The reminder function in the health app, MaPharmacieMobile, is for following a long-term course of treatment. The pharmacist enters the dosage in the app, and the patients are sent alerts on their smartphone telling them the time, the medication and the dosage to take. They then confirm they have taken their medication directly in the app. The DO-Pill SecuR(TM) smart pill dispenser is for older people living independently and taking a number of different medications for optimum treatment monitoring, while receiving the support of a healthcare professional. The pharmacist sets up the DO-Pill to make sure there are no dosage mistakes and that the doctor's prescription is followed to the letter. Outcome: treatment compliance as high as 98%. MULTIMEDS is the medication management system for . The dispensing system is managed by the pharmacist, who is the expert, and administration of the medication is supervised by the care home personnel through the dedicated and secure CAREMEDS interface. The links between health professionals are maintained at all stages of the patient's care pathway, and the pharmacist - the local health professional - is positioned in the pivotal role of health coordinator. Dominique PAUTRAT, Managing Director, PHARMAGEST Group, said: "Compliance is a strategic priority for the PHARMAGEST Group. These two acquisitions fit perfectly with the Group's overarching investment aims over the past five years, and its focus on patients and on improving treatment compliance. We made the trail-blazing decision in 2011 to invest in DO-Pill SecuR(TM) (to increase the safety of medication administration), while simultaneously launching the mobile app, Ma Pharmacie Mobile® (a reminder system). Our Offidose range introduced in 2015 equips care homes and pharmacies with software to track compliance and medication, while the compliance monitoring software (LSO) launched in 2016 offers a solution to understand and manage treatment." He added: "Adding a compliance monitoring system in the form of blister pack trays was the logical next step and gives us an alternative that is far more accessible than DO-Pill SecuR(TM), which is designed for acute and complex medicines. The CAREMEDS and MULTIMEDS acquisitions expand the PHARMAGEST Group range of products and services and increase our capability to provide the infrastructure and solutions for virtually every type of compliance problem in France and Europe, with systems that are centred on the patient, keep the pharmacist at the commands and link hospitals at home (HAD), doctors, nurses, and home-based nursing services." The PHARMAGEST Group is the French leader in pharmacy information technology, with a 43.5% share of the market and over 860 employees. The Group's strategy is based on a core business, innovation and information technology to improve health care, and on the development of two priorities: 1/ Services and technologies for healthcare professionals, with a focus on assisting pharmacies with monitoring patient compliance; and 2/ technology for improving the efficacy of healthcare systems. To roll out that strategy, the PHARMAGEST Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for pharmaceutical laboratories, connected health devices and apps, and a sales financing marketplace. These businesses are now divided into four divisions: the Solutions for Pharmacy Division - Europe, the Solutions for Sanitary and Medico-Social Establishments Division, the Solutions for e-Health Division, and the FinTech Division. Listed on the NYSE Euronext Paris(TM) - Compartment B Indices: ENTERNEXT TECH 40, CAC ® SMALL and CAC ® All-Tradable par inclusion Eligible for the Long-Only Deferred Settlement Service (SRD) ISIN: FR0012882389 - Reuters: PHA.PA - Bloomberg: - PMGI FP For all the latest news on the PHARMAGEST Group, go to www.pharmagest.com


News Article | February 15, 2017
Site: globenewswire.com

The consolidated unaudited turnover of the PHARMAGEST Group in 2016 amounted to €128.38 million, up 13.13% from the previous year. Growth was strong in the fourth quarter, but remained lower than prior quarters due to the impact of a base effect on the Fintech business. Although turnover fell by a slight 0.5% relative to 31 December 2015, driven down by the effect of a negative stage of the rental contracts cycle in the year, recurring sales rose +2.3%. The Division also successfully adjusted its offering (1% growth in turnover on "new products"). The Solutions for Pharmacy Division - Europe accounted for 76.4% of PHARMAGEST Group's total turnover in 2016 (versus 87% in 2015). Turnover in this Division was up 49.6% year-on-year to €10.29 million at 31.12.2016 (like-for-like growth in 2015 was 19.8%), boosted by the combined effect of the momentum in this market, the expansion of its line-up and the March 2016 acquisition of DICSIT INFORMATIQUE (IT company specialising in home hospitalisation). The Division accounted for 8% of the PHARMAGEST Group's full-year turnover, up from 6.1% in 2015. The main growth driver in this Division was the sale of the connected objects developed by PHARMAGEST Group featuring built-in intelligence features engineered to meet the needs and expectations of healthcare professionals. Acquisitions in 2016 (NOVIATEK and SAILENDRA) had yet to make any significant contribution to the Division's turnover. The Solutions for e-Health Division contributed 7.7% of the PHARMAGEST Group's total turnover in 2016, up from 5.7% in 2015. In 2017, the PHARMAGEST Group intends to pursue its strategy of growth and innovation. The new partnership deal with Belgian pharmacy group MULTIPHARMA (the leading Belgian pharmaceutical distributor) is expected to strengthen the Group's presence in Belgium, anchored by its SABCO subsidiary and open up further development opportunities in 2017. At the same time, the performance of the Group's growth drivers, namely the Solutions for sanitary and medico-social establishments and Solutions for e-Health Divisions, confirms the suitability of this diversification strategy. With the acquisitions completed in 2016 - DICSIT INFORMATIQUE (in March), NOVIATEK (in June) and SAILENDRA (in December) - the PHARMAGEST Group will step up its R&D strategy focusing on new patient-centred solutions, and further consolidate its leadership in the various connected health markets. Buoyed by the robust performance of the Fintech Division after only one year in operation (founded in 2015 to build a sales financing marketplace for equipment and services through the NANCEO subsidiary), the PHARMAGEST Group confirms its goal of developing its offering in other segments, in France as well as in the international market. The PHARMAGEST Group formed an International Development Department to lead its external growth strategy and the first strategic partnerships should be agreed in 2017. Publication of 2016 results and presentation meeting in Paris on 03 April 2017   The PHARMAGEST Group is the French leader in pharmacy information technology, with a 43.5% share of the market and over 860 employees. The Group's strategy is based on a core business, innovation and information technology to improve health care, and on the development of two priorities: 1/ Services and technologies for healthcare professionals, with a focus on assisting pharmacies with monitoring patient compliance; and 2/ technology for improving the efficacy of healthcare systems. To roll out that strategy, the PHARMAGEST Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for pharmaceutical laboratories, connected health devices and apps, and a sales financing marketplace. These businesses are now divided into four divisions: the Solutions for Pharmacy Division - Europe, the Solutions for Sanitary and Medico-Social Establishments Division, the Solutions for e-Health Division, and the FinTech Division. Listed on the NYSE Euronext Paris(TM) - Compartment B Indices: ENTERNEXT TECH 40, CAC ® SMALL and CAC ® All-Tradable par inclusion Eligible for the Long-Only Deferred Settlement Service (SRD) ISIN: FR0012882389 - Reuters: PHA.PA - Bloomberg: - PMGI FP For all the latest news, go to www.pharmagest.com

Loading Pharmacy Division collaborators
Loading Pharmacy Division collaborators